图文详情
SHP2/CDK4-IN-1 (compound 10) is a dual inhibitor targeting SHP2 and CDK4, exhibiting oral activity and high potency with IC50 values of 4.3 nM for SHP2 and 18.2 nM for CDK4. It effectively induces G0/G1 arrest, inhibiting the proliferation of TNBC cell lines, and demonstrates significant antitumor efficacy in the EMT6 syngeneic mouse model. This compound is valuable for research into triple-negative breast cancer (TNBC) [1].